신호전달체계의 조절을 통한 천식의 새로운 치료제 개발

참고문헌 (60)

1. "From bronchoconstriction to airways inflammation and remodeling", 161, pp.1720~1745 (2000)
2. "Novel signal transduction modulators for the treatment of airway diseases", 109, pp.238~245 (2006)
3. "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators", pp.645~50
4. "Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more", 2, pp.261~266 (1995)
5. "Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation", 85, pp.267~273 (2003)
6. "An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer", 55, pp.932~943 (1995)
7. "PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines", 391, pp.82~86 (1998)
8. "The PPARs: from orphan receptors to drug discovery", 43, pp.527~550 (2000)
9. "15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma", 83, pp.803~812 (1995)
10. "Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells", pp.1070~6
11. "Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility", 42, pp.1~53 (2004)
12. "Studies on antidiabetic agents Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents", pp.2617~26
13. "Novel PPARgamma-dependent and independent effects for thiazolidinediones", 14, pp.651~652 (2003)
14. "Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?", 13, pp.215~228 (2004)
15. "Peroxisome proliferator-activated receptor- gamma calls for activation in moderation lessons from genetics and pharmacology", 25, pp.899~918 (2004)
16. "Peroxisome proliferator-activated receptor- gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity", 276, pp.12629~12635 (2001)
17. "Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents", 3, pp.239~251 (2003)
18. "PPARs in diseases: control mechanisms of inflammation", 12, pp.2995~3009 (2005)
19. "New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists", 10, pp.3505~3524 (2004)
20. "Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy", 170, pp.2663~2669 (2003)
21. "Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?", 41, pp.23~34 (2006)
22. "85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells", 277, pp.33153~33163 (2002)
23. "Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling", 164, pp.1487~1494 (2001)
24. "Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation", 198, pp.411~421 (2003)
25. "Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model", 113, pp.882~888 (2004)
26. "PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma in vitro evidence for an NF-kappaB-independent effect", 139, pp.163~171 (2003)
27. "Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma", 418, pp.186~196 (2003)
28. "Activation of peroxisome proliferator- activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma", 164, pp.263~271 (2004)
29. "PPAR-gamma modulates allergic inflammation through up- regulation of PTEN", 19, pp.1033~1035 (2005)
30. "Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma", 68, pp.1568~1575 (2005)
31. "PPARγ modulates reactive oxygen species generation and activation of NF-κB and HIF-1α in allergic airway disease of mice", 118, pp.120~127 (2006)
32. "Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists interactions with glucocorticoids and beta2- agonists", 280, pp.2550~2561 (2005)
33. "Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells", 58, pp.778~783 (2003)
34. "Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN", 11, pp.768~8 (2001)
35. "Oxidant stress in asthma", 55, pp.51~53 (2000)
36. "Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation", 28, pp.195~203 (2004)
37. "Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation", 23, pp.2203~2208 (2003)
38. "Phosphoinositide 3-kinase in immunological systems", 14, pp.7~18 (2002)
39. "The role of PI3K in immune cells", 4, pp.313~319 (2003)
40. "The docking molecule Gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common γ chain-uring cytokines", 275, pp.26959~26966 (2000)
41. "Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT", 198, pp.1573~1582 (2003)
42. "PI3K-mediated negative feedback regulation of IL-12 production in DCs", 3, pp.875~881 (2002)
43. "Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma", 111, pp.1083~1092 (2003)
44. "An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model", 5, pp.495~502 (2005)
45. "Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation", 69, pp.1829~1839 (2006)
46. "Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model", 20, pp.455~465 (2006)
47. "Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease", 321, pp.1~8 (2007)
48. "Implication of phosphatidylinositol 3-kinase membrane recruitment in hydrogen peroxide-induced activation of PI3K and Akt", 42, pp.2995~3003 (2003)
49. "Serum withdrawal kills U937 cells by inducing a positive mutual interaction between reactive oxygen species and phosphoinositide 3-kinase", 17, pp.197~204 (2005)
50. "Hydrogen peroxide induces vascular permeability via regulation of vascular endothelial growth factor", 35, pp.190~197 (2006)
51. "A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma", 68, pp.1281~1290 (2005)
52. "Phosphoinositide 3-kinases: a conserved family of signal transducers", 22, pp.267~272 (1997)
53. "Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue", 103, pp.3448~3456 (2004)
54. "Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice", 297, pp.1031~1034 (2002)
55. "Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement", 170, pp.2647~2654 (2003)
56. "Essential role for the p110delta phosphoinositide 3-kinase in the allergic response", 431, pp.1007~1011 (2004)
57. "Contribution of vascular endothelial growth factor to airway hyper-responsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma", 168, pp.3595~3600 (2002)
58. "Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung", 10, pp.1095~1103 (2004)
59. "Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing VEGF expression", 114, pp.1093~1099 (2004)
60. "Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma", 118, pp.403~409 (2006)

관련 논문AI추천